Kura Oncology (KURA) Net Cash Flow (2010 - 2026)
Kura Oncology (KURA) posted quarterly Net Cash Flow of -$110.0 million for Q1 2026, up 36.48% year-over-year from -$80.6 million in Q1 2025, and down 304.45% quarter-over-quarter from $53.8 million in Q4 2025.
Kura Oncology (KURA) Net Cash Flow (2010 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Net Cash Flow for 17 consecutive years, with -$110.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 36.48% year-over-year to -$110.0 million; the TTM figure through Mar 2026 stood at -$12.2 million (down 224.82% YoY), while the FY2025 annual figure was -$75.4 million, down 140.27% from the prior year.
- Net Cash Flow slipped to -$110.0 million in Q1 2026 per KURA's latest filing, from $53.8 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $175.0 million in Q4 2024 and bottomed at -$173.2 million in Q1 2025.
- Historically, Net Cash Flow has averaged -$8.6 million across 5 years, with a median of $4.2 million in 2024.
- Annual changes were most pronounced in 2022 — Net Cash Flow surged 24627.27% — and 2025, when it tumbled 4235.46%.
- Kura Oncology's Net Cash Flow stood at -$39.1 million in 2022, then soared by 121.92% to $8.6 million in 2023, then surged by 1939.89% to $175.0 million in 2024, then tumbled by 69.25% to $53.8 million in 2025, then tumbled by 304.45% to -$110.0 million in 2026.
- Business Quant data shows KURA's Net Cash Flow at -$110.0 million in Q1 2026, $53.8 million in Q4 2025, and $13.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | 31.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.16 Mn |
| Jun 30, 2026 | 31.16 Mn |
| Mar 31, 2026 | -110.02 Mn |
| Mar 31, 2026 | -110.02 Mn |
| Dec 31, 2025 | 53.81 Mn |
| Dec 31, 2025 | 53.81 Mn |
| Sep 30, 2025 | 13.34 Mn |
| Sep 30, 2025 | 13.34 Mn |
| Jun 30, 2025 | 30.68 Mn |
| Jun 30, 2025 | 30.68 Mn |
| Mar 31, 2025 | -173.19 Mn |
| Mar 31, 2025 | -173.19 Mn |
| Dec 31, 2024 | 174.98 Mn |
| Dec 31, 2024 | 174.98 Mn |
| Sep 30, 2024 | 4.30 Mn |
| Sep 30, 2024 | 4.30 Mn |
| Jun 30, 2024 | 3.68 Mn |
| Jun 30, 2024 | 3.68 Mn |
| Mar 31, 2024 | 4.19 Mn |
| Mar 31, 2024 | 4.19 Mn |